<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05107453</url>
  </required_header>
  <id_info>
    <org_study_id>MMS.2021.042</org_study_id>
    <nct_id>NCT05107453</nct_id>
  </id_info>
  <brief_title>Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery</brief_title>
  <official_title>Serratus Anterior Plane Block for Minimal Invasive Cardiac Surgery: a Single Center Randomized-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Algemeen Ziekenhuis Maria Middelares</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Algemeen Ziekenhuis Maria Middelares</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analgesia in cardiac surgery is historically based on large doses of intravenous opiods.&#xD;
      However, this practice is rapidly changing due to &quot;Enhanced Recovery After Surgery (ERAS)&quot;&#xD;
      protocols with proven benefits on morbidity and mortality. Also, the opioid crisis caused by&#xD;
      opioid abuse, has changed anaesthesia practice to reduce the use of opioids after surgery.&#xD;
      Therefore, perioperative multimodal pain management with regional anaesthesia in minimal&#xD;
      invasive cardiac surgery (MICS) has gained a lot of interest.&#xD;
&#xD;
      Serratus Anterior Plane Block (SAPB) is one example of the fascial plane chest wall blocks&#xD;
      and aims at achieving complete sensory loss of the anterolateral hemithorax via blockade of&#xD;
      the lateral cutaneous branches of the thoracic intercostal nerves (T2-T12). SAPB has already&#xD;
      proved its efficacy in thoracic surgery as it reduced pain scores and opioid consumption&#xD;
      compared to systemic analgesia in the first 12-24h after surgery. However only few studies&#xD;
      investigated the effects of SAPB in minimal invasive cardiac surgery.&#xD;
&#xD;
      Therefore the primary aim of this study is to investigate the analgesic effects of a&#xD;
      superficial SAPB in Minimal Invasive Cardiac Surgery compared to a control group with&#xD;
      standard intravenous opioid analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2 x 40 patients scheduled for mitral valve surgery via port access, aortic valve replacement&#xD;
      via right anterior thoracotomy and minimal invasice direct coronary artery bypass (MIDCAB)&#xD;
      surgery will be randomized in a control or SAPB group.&#xD;
&#xD;
      Every patient will receive the standard anaesthetic treatment. At the end of the surgery,&#xD;
      patients in the SAPB group will receive levobupivacaine 0.25 %, 2.5 mg/ml (dosage scheme:&#xD;
      1.25 mg/kg levobupivacaine 0.25%, with a maximum of 100 mg). Levobupivacaine will be given&#xD;
      via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus&#xD;
      dorsi and serratus anterior muscle, at the end of the surgery.&#xD;
&#xD;
      For both the SAPB group and the control group, the ICU nurse will repeatedly administer&#xD;
      piritramide 2 mg intravenously, till numerical rating scale (NRS) are less than 4. Also&#xD;
      paracetamol 1 g will be continoued 4 times daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Patient, intensivist, ICU nurses and data manager are blinded for the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic effect of superficial SAPB in MICS</measure>
    <time_frame>In the first 48 hours after surgery</time_frame>
    <description>Numeric (pain) Rating Scale every 2 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Analgesic effect of superficial SAPB in MICS</measure>
    <time_frame>In the first 48 hours after surgery</time_frame>
    <description>Total opioid consumption in the intensive care unit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative nausea and vomiting</measure>
    <time_frame>In the first 48 hours after surgery</time_frame>
    <description>PONV every 2 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to extubation in the intensive care unit</measure>
    <time_frame>From arrival on the ICU until discharge on the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>From arrival on the ICU until discharge on the ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PaCO2</measure>
    <time_frame>In the first 48 hours after surgery</time_frame>
    <description>PaCO2 every 4 hours, calculated by an arterial blood gas test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Minimal Invasive Cardiac Surgery</condition>
  <condition>Mitral Valve Surgery</condition>
  <condition>Aortic Valve Replacement</condition>
  <condition>Minimal Invasive Direct Coronary Artery Bypass</condition>
  <arm_group>
    <arm_group_label>SAPB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The IMP is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.&#xD;
The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobupivacaine</intervention_name>
    <description>The IMP is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.&#xD;
The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery.</description>
    <arm_group_label>SAPB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients scheduled for mitral valve surgery via port access, aortic valve replacement via&#xD;
        right anterior thoracotomy and minimal invase direct coronary artery bypass&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding&#xD;
&#xD;
          -  BMI &gt;35&#xD;
&#xD;
          -  Opioid abuse&#xD;
&#xD;
          -  Patients known with chronic pain&#xD;
&#xD;
          -  Patients known with allergy to local anaesthetics (in this case levobupivacaine)&#xD;
&#xD;
          -  Patients known with hypersensitivity to piritramide&#xD;
&#xD;
          -  Patients who receive medication that could possibly interact with levobupivacaine (sa.&#xD;
             mexilatine, ketoconazol, theophylline)&#xD;
&#xD;
          -  Patients who simultaneously participate in another interventional clinical trial,&#xD;
             unless the Principal Investigators of the clinical trials give consent by mutual&#xD;
             agreement that the patient can participate in another interventional clinical trial&#xD;
&#xD;
          -  Soft tissue infection in the area of the procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffi Ryckaert, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Algemeen Ziekenhuis Maria Middelares</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bart Vaes, MD</last_name>
    <phone>+32 9 246 17 35</phone>
    <email>bart.vaes@azmmsj.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Vaes, MD</last_name>
      <phone>+32 9 246 17 35</phone>
      <email>bart.vaes@azmmsj.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Algemeen Ziekenhuis Maria Middelares</investigator_affiliation>
    <investigator_full_name>Bart Vaes, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

